Purchase Order 75N95021P00341
Award Date 7/12/21
Potential Completion Date 8/23/21
Potential Value $36K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Malvern, PA 19355, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $118,430.00 firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract is for testing 15 novel small molecule compounds using Reaction Biology's proprietary Kinase HotSpot assay platform. This work supports translational research efforts across the NIH. The purchase order was...
- The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $110,000.00 firm fixed price purchase order to Reaction Biology Corporation, a self-certified small disadvantaged business, for the testing of compounds to inhibit wild-type kinase enzymes. This requirement does not have a set-aside designation. Reaction Biology Corporation is a contract research organization that provides specialized bioassay testing and...
- This is a firm-fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Reaction Biology Corporation. The $80,000.00 contract is for the provision of specialized preclinical services, including enzyme activity assays, screening, and related laboratory services to support biomedical research initiatives. Reaction Biology, a self-certified small disadvantaged business, has primarily...
- The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, awarded a firm-fixed-price purchase order contract worth $18,028.80 to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract, which does not have a set-aside designation, was awarded on June 5, 2019, with a completion date of December 13, 2019. Reaction Biology Corporation, a drug discovery contract research organization,...
- This $125,600.00 firm fixed-price purchase order was awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business, to conduct testing of novel small molecule compounds for kinase inhibition. The contract does not have a set-aside designation. The work involves screening 300 compounds against 3 wild-type kinases and 10 compounds against a panel of 50 wild-type kinases using...
- This is a firm fixed-price purchase order awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business. The $21,027.68 contract is for the testing of 2 compounds against a selected kinase panel in a biochemical gamma 33P-ATP kinase assay. Reaction Biology specializes in enzyme activity assays and has previously provided kinase inhibition testing, cancer cell line screening, and...
- This $29,376 firm-fixed-price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Reaction Biology Corporation, a self-certified small disadvantaged business. The award is to obtain kinase hotspot assay compound testing services from Reaction Biology. This contract is not associated with a larger vehicle. The purpose is to test 120 novel small molecule compounds for inhibitory activity...
- This is a firm fixed price purchase order awarded by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse to Reaction Biology Corporation, a small disadvantaged business contractor. The contract is for the testing of compounds for inhibition of 370 wild-type kinase enzymes, with a potential value of $166,500.00 and a completion date of December 6, 2022. Reaction Biology has previously provided kinase inhibition testing, cancer cell line...
- This is a $19,840.00 firm-fixed price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract is for biochemical kinase assays on 160 compounds to determine their inhibitory activity against the kinases LATS1, LATS2, and AKT, which will inform the development of potential anti-cancer agents. This award was a...
- This is a firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Drug Abuse to Reaction Biology Corporation, a self-certified small disadvantaged business. The $143,260.00 contract is for kinase screening services, with Reaction Biology testing 377 wild-type kinases against 10 compounds. The award stems from a non-competitive solicitation issued by the NIH's National Center for Advancing Translational...